Ab­b­Vie's Skyrizi hangs No­var­tis' Cosen­tyx out to dry in head-to-head pso­ri­a­sis study

6 years ago
Pharma

#JPM20: 'The NPV is al­ways wrong.' Take­da preps an­oth­er spin­out — this time on psych

6 years ago
R&D
Pharma

Roche aims to 'un­der­whelm' with ris­diplam price as it en­ters SMA ri­val­ry with Bio­gen, No­var­tis — re­port

6 years ago
Pharma

‘Clin­i­cal su­pe­ri­or­i­ty’: di­azepam nasal spray il­lus­trates FDA pa­ra­me­ters for or­phan drug ex­clu­siv­i­ty

6 years ago
R&D
FDA+

Still to be ap­proved in­clisir­an gets red car­pet treat­ment by UK's NHS in deal with No­var­tis

6 years ago
Deals

New Adap­ti­m­mune man­age­ment scores con­fi­dence boost with up to $897M+ Astel­las deal

6 years ago
Deals

Gates vets at Ad­ju­vant back Coda­genix's soft­ware-dri­ven ap­proach to re­cod­ing RSV, flu, on­colyt­ic virus­es and more

6 years ago
Financing
Startups

PACT Phar­ma bags $75M for neoanti­gen TCR work, man­u­fac­tur­ing; Bay­er grabs ex­per­i­men­tal con­tra­cep­tive from Daré

6 years ago
News Briefing

An­oth­er opi­oid pain drug, re­al­ly? FDA staff sound sour on Nek­tar anal­gesic

6 years ago
R&D

Ahead of ad­u­canum­ab fil­ing, Bio­gen nabs Pfiz­er castoff for $75M to ad­dress Alzheimer's, Parkin­son's symp­toms

6 years ago
Deals

Shoot­ing for $100M IPO, Schrödinger takes the wraps off its five in­ter­nal drugs and dis­clos­es deal de­tails

6 years ago
Financing

Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

6 years ago
R&D
Pharma

Bio­phar­ma ends decade with near-record in­vest­ment — but is it go­ing to the right places?

6 years ago
Financing

With sparse R&D prospects, In­cyte bets $900M on Mor­phoSys' CAR-T ri­val taf­a­sita­m­ab

6 years ago
Deals

RA Cap­i­tal, Canaan help in­fuse $50M in­to Al­ta-in­cu­bat­ed biotech bat­tling ac­quired re­sis­tance to TKIs

6 years ago
Financing
Startups

Watch live: End­points at #JPM20

6 years ago

Alex­is Borisy has $200M to back a mar­ket-based plan aimed at cur­ing Amer­i­ca’s drug pric­ing ‘sick­ness’

6 years ago
Financing
Pharma

J&J plans to re­cruit a new gen­er­a­tion of 'bilin­gual' sci­en­tists for a re­search fa­cil­i­ty blue­print­ed for the boom­ing ...

6 years ago
Pharma

Eli Lil­ly vet jumps aboard Po­laris Part­ners; Mi­rati shakes up its lead­er­ship team with new hires and pro­mo­tions

6 years ago
Peer Review

23andMe finds a buy­er for its IL-36 bis­pe­cif­ic in Almi­rall; Neu­ro­crine, Idor­sia re­vise epilep­sy drug deal

6 years ago
News Briefing

That com­pa­ny su­ing Patrick Soon-Sh­iong for $1B? Some­one's try­ing to buy it for $1B

6 years ago
R&D

What are bio­phar­ma com­pa­nies hir­ing CROs for these days? PPD spells it out in bid for $100M IPO

6 years ago
Financing
Outsourcing

With $110M to add to the bankroll, Gen­er­a­tion Bio sets its sights on en­gi­neer­ing a rev­o­lu­tion in the gene ther­a­py ...

6 years ago
Financing
Cell/Gene Tx

Tar­get­ing the BF­Ps of the CNS, Bio­gen li­cens­es map of ge­net­ic neigh­bor­hoods in the brain

6 years ago
R&D
First page Previous page 863864865866867868869 Next page Last page
A service from the Financial Times